AD/PD™ 2025 Parkinson’s Disease Conference

🧠 Lys Therapeutics at ADPD2025 – Advancing Parkinson’s Disease Research

We are pleased to share that Lys Therapeutics and our Co-founder & CEO, Dr. Manuel Blanc, will be participating in the AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, taking place April 1–5, 2025 in Vienna, Austria 🇦🇹 (adpd.kenes.com).

As part of our continued effort to develop novel treatments for neurodegenerative diseases, we will present a scientific poster showcasing our latest preclinical results in Parkinson’s disease:

🎯 “A Novel Therapeutic For The Treatment Of Parkinson’s Disease Targeting The tPA-NMDAR Interaction”

Our disease-modifying antibody has demonstrated robust efficacy even when administered at late stages of the disease, highlighting its potential to benefit patients beyond early intervention windows, to slow-down or prevent disease progression.

🧬 We are proud to contribute to advancing the field of neuroscience and look forward to engaging with the scientific and medical community at AD/PD™ 2025.

📩 Interested in partnering or learning more? Let’s connect in Vienna!

ParkinsonsDisease Neuroscience Biotech Immunotherapy tPANMDAr Neurodegeneration ADPD2025 LysTherapeutics LYS241 glunomab InnovationInNeuroscience